Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02979522 · ClinicalTrials.gov registry record · Phase 1

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

A Phase 1 study of Hodgkin Disease, sponsored by Takeda.

Active
Registry status
Phase 1
Development phase
59
Enrollment target
14
Study locations

NCT02979522 is a Phase 1 study of Hodgkin Disease that is active but no longer recruiting, run by Takeda. The registered enrollment target is 59 participants, below the 275-participant average among 20 other Hodgkin Disease trials with a reported enrollment target (79% lower). The trial reports 14 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02979522, a Phase 1 study of Hodgkin Disease, is active but no longer recruiting, sponsored by Takeda.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
59 participants
Enrollment target
14
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).

Conditions Studied

Hodgkin Disease

Interventions

  • DRUG Doxorubicin
  • DRUG Brentuximab vedotin
  • DRUG Dacarbazine
  • DRUG Vinblastine

Study Locations (14)

Other

  • Jardim das Americas - Paranã
  • INCA - Instituto Nacional de Cancer - Rio de Janeiro
  • GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer - São Paulo
  • ICr - Instituto da Crianca - HCFMUSP - São Paulo
  • Hospital Santa Marcelina - São Paulo
  • Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer - Florence
  • Fondazione IRCCS Policlinico San Matteo - Pavia
  • Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia - Roma
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino - Torino

Colorado

  • Children's Hospital Colorado - Aurora

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Estado de Bahia

  • Hospital Sao Rafael S/A - Salvador

Aichi-ken

  • NHO Nagoya Medical Center - Nagoya

Kanagawa

  • St. Marianna University School of Medicine Hospital - Kawasaki-shi

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2017-09-06
Est. Completion 2029-09-24
Phase Phase 1

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02979522

The ClinicalTrials.gov registry entry for NCT02979522 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 20 other Hodgkin Disease trials with a reported enrollment target (79% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hodgkin Disease appearing as the primary indexed condition, and to 4 interventions - of which Doxorubicin is the first listed.

NCT02979522 reports 14 study locations spanning 6 distinct geographic areas - top geographies include Other, Colorado, Ohio.

Frequently Asked Questions

What is clinical trial NCT02979522 about?

NCT02979522 is a clinical study titled "A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma". The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants...

What is the current status of trial NCT02979522?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2017-09-06. Estimated completion is 2029-09-24.

What conditions does trial NCT02979522 study?

This clinical trial studies the following conditions: Hodgkin Disease.

What interventions are being tested in trial NCT02979522?

The interventions under investigation include: Doxorubicin (DRUG), Brentuximab vedotin (DRUG), Dacarbazine (DRUG), Vinblastine (DRUG).

Who is sponsoring clinical trial NCT02979522?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02979522 being conducted?

This trial has 14 study locations across Colorado, Ohio, Estado de Bahia, Aichi-ken, Kanagawa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hodgkin Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hodgkin Disease

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.